 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Phase II/III Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM)
|
|
|
|
Phase III, Phase II
|
|
|
|
Protocol CDX110-003
NCT00458601
|
|
| |
Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
|
|
|
|
Phase III
|
|
|
|
RTOG-0525
RTOG-0525, EORTC-26052, EORTC-22053, NCT00304031
|
|
| |
Effect of NovoTTF-100A in Recurrent GBM
|
|
|
|
Phase III
|
|
|
|
EF-11
NCT00379470
|
|
| |
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-Tenascin Radiolabeled Antibody Therapy
|
|
|
|
Phase III
|
|
|
|
BRAD-301
NCT00615186
|
|
| |
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
|
|
|
|
Phase II, Phase I
|
|
|
|
NABTC-0402
NCI-06-C-0053, NABTC-04-02, NCT00112736
|
|
| |
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
|
|
|
|
Phase II, Phase I
|
|
|
|
SJCRH-SJHG04
GENENTECH-OSI3160s, NCT00124657
|
|
| |
A Phase I/II Study of the Photon Radiosurgery System
|
|
|
|
Phase II, Phase I
|
|
|
|
CNS 0201
NCT00179907
|
|
| |
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
|
|
|
|
Phase II, Phase I
|
|
|
|
UCSF-05103
05103, UCSF-H41995-27311-01, NCT00293423
|
|
| |
ZD6474 in Treating Patients With Recurrent or Progressive Gliomas
|
|
|
|
Phase II, Phase I
|
|
|
|
NCI-06-C-0063
NCI-P6680, NCT00293566
|
|
| |
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|
|
|
|
Phase II, Phase I
|
|
|
|
RTOG-0513
RTOG-0513, NCT00305864
|
|
